Preview

Rational Pharmacotherapy in Cardiology

Advanced search

A COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC BISOPROLOL IN MONOTHERAPY OR IN COMBINATION WITH S-AMLODIPINE AND INDAPAMIDE IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 DEGREES. RESULTS OF THE CLINICAL RANDOMIZED CROSSOVER STUDY

https://doi.org/10.20996/1819-6446-2011-7-2-167-173

Full Text:

Abstract

Aim. To study the clinical equivalence of original and generic drugs of bisoprolol in patients with arterial hypertension (HT) 1-2 degrees according to protocol recommended by the Society of Cardiology of the Russian Federation for comparative studies. Material and methods. 30 patients with HT 1-2 degrees were examined. Patients were randomized into group 1 (original bisoprolol 5 mg/day) or group 2 (generic bisoprolol 5 mg/day). In case of insufficient antihypertensive effect bisoprolol dose was increased or S-amlodipine and then indapamide were added. After the first treatment period (8 weeks) was completed 2-week wash-out period started and then the second period (8 weeks) of treatment (taking alternative medicine of bisoprolol) began. Blood pressure (BP), heart rate, ECG, adverse effects were recorded in patients. Results. After 8 weeks of therapy BP reduction was 27.2±12.2/12.0±6.1 mm Hg in group 1 and 29.9±10.5/12.5±7.2 mm Hg in group 2 (p<0.001 for both groups), intergroup differences were insignificant. Target BP levels were achieved in 79.3% of patients in both groups. Heart rate decrease was 11.1±12.9 in group 1 and 8.5±8.6 beats/min in group 2 (p<0.05 for both groups). Significant dynamics of PQ interval were not found in both groups. The groups were comparable in terms of treatment safety and tolerability. Conclusion. Therapeutic equivalence of original and generic bisoprolol is shown in patients with HT 1-2 degrees.

About the Authors

S. Yu. Martsevich
State Research Center for Preventive Medicine
Russian Federation


S. N. Tolpygina
State Research Center for Preventive Medicine
Russian Federation


V. P. Voronina
State Research Center for Preventive Medicine
Russian Federation


O. V. Lerman
State Research Center for Preventive Medicine
Russian Federation


Yu. V. Lukina
State Research Center for Preventive Medicine
Russian Federation


N. A. Dmitrieva
State Research Center for Preventive Medicine
Russian Federation


I. V. Vashurina
State Research Center for Preventive Medicine
Russian Federation


References

1. 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007;28:1462-36.

2. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291:97-104.

3. IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). J Hypertens 1985; 3: 379-392.

4. Wilhelmsen L., Berglund G., Elmfeldt D. et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987; 5: 561-572.

5. Wikstrand J., Warnold I., Tuomilehto J. et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from MAPHY study. Hypertension 1991; 17: 570-588.

6. Hansson L., Lindholm L., Dahlof B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.

7. Pepine C.J., Handberg E.M., Cooper-DeHoff R.M. et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290: 2805-2816.

8. Hansson L., Hedner T., Lund-Johansen P. et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365.

9. Martsevich S.Yu., Tolpygina S.N., Boychenko E.S. et al. Comparison of antiplatelet efficacy of original and generic enterosoluble acetylsalicylic acid in patients with high cardiovascular risk. Simple blind crossed randomized controlled study (IKAR). Rational Pharmacother Card 2010;6(6):796-802. Russian (Марцевич С.Ю., Толпыгина С.Н., Бойченко Е.С. и др. Сравнительное изучение дезагрегантной эффективности оригинального и воспроизведенного препарата ацетил-салициловой кислоты в кишечно-растворимой форме у пациентов высокого риска сердечно-сосудистых осложнений. Простое слепое перекрестное рандомизированное контролируемое исследование (ИКАР). РФК 2010;6(6):800-806).

10. Lukina J.V., Deev A.D., Dmitrieva N.A. et al. Comparative study of new drug of long acting metoprolol tartrate — Egilok retard and original drug of metoprolol succinate — Betaloc ZOK in patients with mild to moderate arterial hypertension Rational Pharmacother Card 2005;3:35-40. Russian (Лукина Ю.В., Деев А.Д, Дмитриева Н.А. и др. Сравнительное изучение нового препарата метопролола тартрата пролонгированного действия — эгилока ретард и оригинального препарата метопролола сукцината — беталока ЗОК у больных мягкой и умеренной артериальной гипертонией. РФК 2005;3: 35-40).

11. Martsevich S.Yu., Kutishenko N.P., Deev A.D. et al. Therapeutic equivalence of two amlodipine preparations (original and generic) in patients with arterial hypertension. Results of a double-blind, randomized cross-over study. Rossiyskiy kardiologicheskiy zhurnal 2004; 4: 53-56. Russian (Марцевич С.Ю., Кутишенко Н.П., Деев А.Д. и др. Изучение терапевтической эквивалентности двух препаратов амлодипина (оригинального и воспроизведенного) у больных артериальной гипертонией. Результаты двойного слепого рандомизированного перекрестного исследования. Российский кардиологический журнал 2004; 4: 53-56).

12. Nedogoda S.V., Marchenko I.V., Chalyabi T.A. Comparative antihypertensive efficacy of generic ACE inhibitor enalapril-Renitec (Enap, Ednit, Invoril, En-vas and Enam) and the cost of treatment in patients with hypertension. Arterial'naya gipertenziya 2000;1:52-54. Russian (Недогода С.В., Марченко И.В., Чаляби Т.А. Сравнительная антигипертензивная эффектив-ность дженериков ингибитора ангиотензин-превращающего фермента эналаприла-ренитека (энапа, эднита, инворила, энваса и энама) и стоимость лечения у больных гипертонической болезнью. Артериальная гипертензия 2000;1:52-54).

13. Carter B.L., Noyes M.A., Demmler R.W. Differences in serum concentrations of and response to generic verapamil in the elderly. Pharmacotherapy 1993;13:359-368.

14. Martsevich S.Y., Lukina J.V., Deev A.D. et al. Comparative study of combined drugs of enalapril maleate and hydrochlorothiazide: «Renipril HT» and «Co-renitec» in patients with mild to moderate arterial hypertension. Rational Pharmacother Card 2005;3:29-34. Russian (Марцевич С.Ю., Лукина Ю.В., Деев А.Д. и др. Сравнительное изучение комбинированных препаратов эналаприла малеата и гидрохлортиазида: «рениприла ГТ» и «коренитека» у больных мягкой и умеренной АГ. РФК 2005; 3: 29-34).

15. Tolpygina S.N., Shilova E.V., Martsevich S.Y. et al. Comparative evaluation of efficacy and tolerability of original and generic bisoprolol in patients with arterial hypertension 1-2 grade. Rational Pharmacother Card 2007;3:15-21. Russian (Толпыгина С.Н., Шилова Е.В., Марцевич С.Ю. Сравнительное изучение эффективности и переносимости оригинального препарата бисопролола и его дженерика у больных мягкой и умеренной артериальной гипертонией. РФК 2007; 3:15-21).

16. Shostak N.A., Rashid M.A., Arinina E.E. et al. Efficacy and safety of bisogammy and Concor for the treatment of arterial hypertension in patients of middle age. Farmateka 2008; 12(166): 81-89. Russian (Шостак Н.А., Рашид М.А., Аринина Е.Е. и др. Эффективность и безопасность применения бисогаммы и конкора для лечения артериальной гипертонии у больных среднего возраста. Фарматека 2008; 12(166): 81-89).

17. Society of Cardiology of the Russian Federation. National guidelines for a rational pharmacotherapy of patients with cardiovascular diseases. Available on: http://scardio.ru/downloads/c4m0i257/recomendacii.doc. Всероссийское Научное Общество Кардиологов. Национальные рекомендации по рациональной фармакотерапии больных сердечно-сосудистыми заболеваниями. Доступно на: http://scardio.ru/downloads/c4m0i257/re-comendacii.doc.

18. Bakris G.L., Williams M., Dworkin L. et al. for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646–661.

19. Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12):861–869.

20. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the an-giotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.

21. Arima H., Chalmers J., Woodward M. et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201–1208.

22. Zanchetti A., Hansson L., Clement D. et al. HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003; 21:797–804.

23. Freemantle N., Cleland J., Young P. et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med Journal 1999; 318:1730–1737.

24. Shekelle P.G., Rich M.W., Morton S.C. et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41:1529–1538.

25. Zanchetti A. Emerging data on calcium-channel blockers: the COHORT study. Clin Cardiol 2003; 26 (Suppl 2) II: 17–20.

26. Cherubini A., Fabris F., Ferrari E. et al. Comparative effects of lercanidipine, lacidipine and nifidepine GITS on blood pressure and heart rate in elderly hypertensive patients: the Elderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 3: 203–212.

27. Pischon T., Sharma A.M. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001; 2:275–280.

28. Jacob S., Rett K., Henriksen E.J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hyper-tens 1998; 11:1258–1265.

29. Mancia G., Grassi G., Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006; 24:3–10.

30. Martsevich S.Yu., Kutishenko N.P., Yakusevich V.V. Once again the problem of interchangeability of drugs. A look at the generics from the standpoint of evidence-based medicine. Vesti kardiologii 2010: 11-21. Russian (Марцевич С.Ю., Кутишенко Н.П., Якусевич В.В. Еще раз о проблеме взаимозаменяемости лекарств. Взгляд на дженерики с позиций доказательной медицины. Вести кардиологии 2010: 11-21).


For citation:


Martsevich S.Yu., Tolpygina S.N., Voronina V.P., Lerman O.V., Lukina Yu.V., Dmitrieva N.A., Vashurina I.V. A COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF ORIGINAL AND GENERIC BISOPROLOL IN MONOTHERAPY OR IN COMBINATION WITH S-AMLODIPINE AND INDAPAMIDE IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 DEGREES. RESULTS OF THE CLINICAL RANDOMIZED CROSSOVER STUDY. Rational Pharmacotherapy in Cardiology. 2011;7(2):167-173. (In Russ.) https://doi.org/10.20996/1819-6446-2011-7-2-167-173

Views: 596


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)